Il 11 inhibitor drugs

Blocking an inflammatory molecule known as interleukin-11 (IL-11) extends the lifespan of mice, suggesting that drugs inhibiting IL-11 may have anti-ageing effects in people, too. As we get older

Current IL-11 signalling inhibitors include IL-11 mutants 43,44 and antibodies against either IL-11 9,20,45 or IL-11R 11,46,47,48. However, mechanistic understanding of their modes of action is

Chemical injury/stimuli may include drug induced fibrosis, e.g. following chronic administration of drugs Antagonist antibody inhibitor of IL-11 mediated

by J Wei 2024 Cited by 63Bazedoxifene, a third-generation selective estrogen modulator approved by the Food and Drug Administration (FDA), is a novel inhibitor of IL-11/GP130 signaling.

These drugs encompassed tumor necrosis factor alpha (TNF- ) inhibitors, interleukin (IL) 17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors and methotrexate. The weighted average analysis showed that the fastest time for 50% of patients to reach PASI75 was with the IL-17 inhibitors, specifically with brodalumab and bimekizumab tied at 3.4

by P Maroni 2024 Cited by 27Several authors have, indeed, proposed COX-2 inhibitors (NS398, indomethacin, and dexamethasone) as drugs useful for suppressing IL-11-mediated osteolytic bone

A study in Nature in July 2024[1], raised the idea that blocking the interleukin 11 (IL-11) by using an IL-11 antibody could be a

IL-12/IL-23 inhibitor: Stelara (ustekinumab); IL-23 inhibitors: Skyrizi (2024).

They also treated 75-week-old mice equivalent to the age of about 55 years in humans with an injection of an anti-IL-11 antibody, a drug which stops the effects of the IL-11 in the body. The results, published in Nature, were dramatic, with mice given the anti-IL-11 drug from 75 weeks of age until death having their median lifespan